Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00681837
First received: May 19, 2008
Last updated: November 17, 2008
Last verified: November 2008
  Purpose

The purpose of this study is to assess prevalence of gastrooesophageal reflux during childhood and teenage years in France and to describe patients'symptoms and gastrooesophageal reflux management


Condition
Gastroesophageal Reflux

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • assess prevalence of gastrooesophageal reflux during childhood and teenage years in France, particularly 0-1 year-old prevalence and 1-11 year-old prevalence [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • describe patients'symptoms and gastrooesophageal reflux management [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Estimated Enrollment: 2500
Study Start Date: May 2008
Study Completion Date: September 2008
Groups/Cohorts
1
children from 0 to 17 years old

  Eligibility

Ages Eligible for Study:   up to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

children recruited by both GPs and paediatricians

Criteria

Inclusion Criteria:

  • children from 0 to 17years old seen in consultation

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00681837

  Show 25 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Frédéric GOTTRAND CHRU Lille - France
Principal Investigator: Geneviève BONNELYE TNS Healthcare 92120 Montrouge - France
  More Information

No publications provided

Responsible Party: Paula Fernstrom, AstraZeneca
ClinicalTrials.gov Identifier: NCT00681837     History of Changes
Other Study ID Numbers: NIS-GFR-DUM-2008/1
Study First Received: May 19, 2008
Last Updated: November 17, 2008
Health Authority: France: Haute Autorité de Santé Transparency Commission

Keywords provided by AstraZeneca:
gastroesophageal reflux
prevalence
childhood
France

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on April 20, 2014